The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held its annual conference in Baltimore, Md. last month, and Venebio consultant, Carlos H. Rojas-Fernandez, PharmD attended to gather insights on recent developments and trends in the industry.

Rojas-Fernandez’s notes that there were a number of posters from Alkermes in the area of economics and outcomes of treatment-resistant depression, as well as outcomes of patients receiving intramuscular antipsychotics (used for bipolar disorder and schizophrenia). Alkermes currently markets intramuscular aripiprazole (antipsychotic), has NDAs for a novel antidepressant (which are under review by the FDA), a new dosage form for aripiprazole, and has drugs for schizophrenia and MS in Phase III trials.

Similarly, Lundbeck presented on outcomes, side effects, and health care utilization for patients taking atypical antipsychotics for treatment-resistant depression, as well as early use of these drugs in treatment resistant depression. Additionally, Lundbeck has started clinical development of a potential new treatment for Parkinson’s disease.

Amgen presented posters focused on various aspects of migraine treatment, health care utilization and health care costs, and productivity associated with migraines. Recently, the FDA has approved the company’s drug Aimovig™ for migraine prevention.

Some recurring themes throughout this year’s ISPOR event include:

To see more about who attended and presented, visit the ISPOR conference website. ISPOR 2019 will take place in New Orleans, May 18-22, 2019.